World J Surg Surg Res | Volume 6, Issue 1 | Review Article | Open Access
Anitei MG1,2, Corre F3 , Kirilovsky A4,5, Marliot F4,5, Musina A1,6, El Sissy C4,5, Lagorce Pagès C4,5,7, Dimofte G1,2, Scripcariu V1,2, Chaussade S3 and Pagès F4,5 *
1“Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania 2Surgical Oncology Unit, Regional Institute of Oncology, Iasi, Romania 3Department of Gastroenterology & Hepatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, France 4INSERM, Laboratory of Integrative Cancer Immunology, Paris, France 5Immunomonitoring Platform, Laboratory of Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France 6Department of Surgical Oncology, Regional Institute of Oncology (IRO), Iasi, Romania 7Department of Pathology, AP-HP, Georges Pompidou European Hospital, Paris, France
*Correspondance to: Franck PagèsFulltext PDF
Endoscopic treatment for T1 Colorectal Cancers (CRC) generates a risk of metastasis in the draining lymph nodes that have been left in place, and of recurrence after Local Resection (LR). Depending on the risk of Lymph Node Metastasis (LNM) determined by the pathologic assessment, approximately 70% of patients with T1 CRC are classified as high risk, whereas postsurgical pathologic results demonstrate that around 20% of these patients actually have LNM. This highlights the limited diagnostic ability of post-endoscopic pathological examination to predict LNM. There is a need for additional biomarkers to allow robust detection of high-risk patients with T1 tumors, minimizing secondary radical surgery, reducing patient complications, physical burdens, and associated health care costs. The objective of this review is to provide an update on the latest advances in predictive biomarkers for LNM of T1 colorectal tumors. A particular focus will be made on the immune component assessment contribution and Immunoscore test.
Colorectal neoplasms; Lymph nodes; Neoplasm metastasis; Risk factors; Endoscopic submucosal dissection; Immunoscore
Anitiei MG, Corre F, Kirilovsky A, Marliot F, Musina A, El Sissy C, et al. New Biomarkers for T1 Colorectal Tumors Management: Contribution of Immune Component Assessment and Immunoscore Testing. World J Surg Surgical Res. 2023; 6: 1461..